Second INTERMACS annual report: More than 1,000 primary left ventricular assist device implants

被引：256

作者：

Kirklin, James K. ^{[1
]}

Naftel, David C. ^{[1
]}

Kormos, Robert L. ^{[2
]}

Stevenson, Lynne W. ^{[3
]}

Pagani, Francis D. ^{[4
]}

Miller, Marissa A.

Ulisney, Karen L. ^{[6
]}

Gaidwin, J. Timothy ^{[5
,7
]}

Young, James B. ^{[8
]}

机构：

[1] Univ Alabama, Birmingham, AL 35294 USA

[2] Univ Pittsburgh, Med Ctr, Presbyterian Univ Hosp, Pittsburgh, PA USA

[3] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA

[4] Univ Michigan, Ann Arbor, MI 48109 USA

[5] NHLBI, Rockledge Ctr 2, Bethesda, MD 20892 USA

[6] NIH, NHLBI, Div Cardiovasc Dis, Adv Technol & Surg Branch, Rockledge, IL USA

[7] NIH, NHLBI, Div Cardiovasc Dis, Adv Technol & Surg Branch, Bethesda, MD 20892 USA

[8] Cleveland Clin Fdn, Lerner Coll Med, Cleveland, OH 44195 USA

来源：

JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2010年 / 29卷 / 01期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1016/j.healun.2009.10.009

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

INTERMACS has analyzed the first 1000-plus patients with primary implantation of LVADs during a transitional period from pulsatile technology to continuous flow pumps. The shift toward implantation of axial flow technology since its approval by FDA is dramatic. This trend has been accompanied by continued fluctuation in the designation of primary device strategy as BTT, BTC, and DT. Inferences from this database regarding expected midterm survival with device therapy must be interpreted with this understanding. When continuous flow technology is routinely available for long-term DT, and as multiple continuous flow pumps are approved, INTERMACS offers a unique opportunity to compare and contrast these technologies in the setting of evolving indications, changing patient profiles, and refinement of device strategy in the developing landscape of mechanical circulatory support. © 2010.

引用

页码：1 / 10

页数：10

共 3 条

[1] INTERMACS database for durable devices for circulatory support: First annual report [J].

Kirklin, James K. ;

Naftel, David C. ;

Stevenson, Lynne Warner ;

Kormos, Robert L. ;

Pagani, Francis D. ;

Miller, Marissa A. ;

Ulisney, Karen ;

Young, James B. .

JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2008, 27 (10) :1065-1072

[2] The REMATCH trial: Rationale, design, and end points [J].

Rose, EA ;

Moskowitz, AJ ;

Packer, M ;

Sollano, JA ;

Williams, DL ;

Tierney, AR ;

Heitjan, DF ;

Meier, P ;

Ascheim, DD ;

Levitan, RG ;

Weinberg, AD ;

Stevenson, LW ;

Shapiro, PA ;

Lazar, RM ;

Watson, JT ;

Goldstein, DJ ;

Gelijns, AC .

ANNALS OF THORACIC SURGERY, 1999, 67 (03) :723-730

[3]

WARNERSTEVENSON L, 2009, J HEART LUNG TRANSP, V28, P535

← 1 →